Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine · generic available

Bexagliflozin

Drug class: Sodium-Glucose Cotransporter 2 Inhibitor

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Quick answers

What is Bexagliflozin used for?
The FDA-approved label (Brenzavvy, TheracosBio, LLC, June 10, 2026) says: “BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. […]. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Bexagliflozin have a boxed warning?
No. None of the 3 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Bexagliflozin?
No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
Has Bexagliflozin been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Bexagliflozin?
2 companies list prescription products of Bexagliflozin in the FDA NDC Directory, including TheracosBio, LLC and Golden State Medical Supply, Inc..

What Bexagliflozin is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

BRENZAVVY is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitations of Use BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus. […]. …

— FDA label: Brenzavvy, TheracosBio, LLC, effective June 10, 2026. Read the full label on DailyMed →

The FDA has 3 labels for products of this medicine (different makers and forms); uses can differ between them. Check the label that comes with your own medicine.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

0 of 3 FDA labels for this medicine have a boxed warning.

Forms and how it is given

Dosage formsTablet
RouteOral
Prescription products3 in the FDA NDC Directory
Brand namesBrenzavvy

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
NDA214373
BRENZAVVY
TheracosbioJanuary 20, 2023 2, latest June 3, 2026
2026: Labeling · 2023: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2637859, 2637865
SPL set ID of the quoted label3cdf28fc-4194-4ad6-aa03-c9eaa68da83e
FDA labels (SPL)3
FDA applicationsNDA214373
Active ingredients (FDA)BEXAGLIFLOZIN

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Brenzavvy, TheracosBio, LLC, effective June 10, 2026; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers